Fidelity Investments
AMLX icon

Fidelity Investments’s Amylyx Pharmaceuticals AMLX Stock Holding History

Fidelity Investments’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$580M Buy
19,945,501
+3,217,592
+19% +$85.3M 0.03% 475
2026
Q2 		$300M Buy
16,727,909
+97,368
+0.6% +$1.51M 0.01% 752
2026
Q1 		$231M Buy
16,630,541
+112,122
+0.7% +$1.58M 0.01% 793
2025
Q4 		$200M Buy
16,518,419
+5,139,212
+45% +$69.8M 0.01% 862
2025
Q3 		$155M Buy
11,379,207
+8,331,188
+273% +$78.4M 0.01% 964
2025
Q2 		$19.5M Buy
3,048,019
+1,890,031
+163% +$9.19M ﹤0.01% 1709
2025
Q1 		$4.1M Buy
1,157,988
+426,632
+58% +$1.52M ﹤0.01% 2210
2024
Q4 		$2.76M Buy
731,356
+510,355
+231% +$2.4M ﹤0.01% 2342
2024
Q3 		$716K Buy
221,001
+164,622
+292% +$370K ﹤0.01% 2719
2024
Q2 		$107K Buy
56,379
+36,989
+191% +$71.7K ﹤0.01% 3274
2024
Q1 		$55.1K Sell
19,390
-1,416,761
-99% -$18.5M ﹤0.01% 3536
2023
Q4 		$21.1M Buy
1,436,151
+997,465
+227% +$15.3M ﹤0.01% 1603
2023
Q3 		$8.03M Sell
438,686
-10,296
-2% -$218K ﹤0.01% 1894
2023
Q2 		$9.7M Buy
448,982
+441,752
+6,110% +$11.9M ﹤0.01% 1876
2023
Q1 		$212K Sell
7,230
-574
-7% -$19.9K ﹤0.01% 2948
2022
Q4 		$288K Buy
7,804
+7,468
+2,223% +$265K ﹤0.01% 2897
2022
Q3 		$9.46K Sell
336
-122,107
-100% -$3.05M ﹤0.01% 4109
2022
Q2 		$2.36M Buy
122,443
+34,318
+39% +$407K ﹤0.01% 2456
2022
Q1 		$1.13M Buy
+88,125
New +$1.99M ﹤0.01% 2758

Other funds holding AMLX

JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.3B AUM 33.78% 1-Year Est. Return

Fidelity Investments's AMLX Position: Q3 2026 in Review

Fidelity Investments increased its Amylyx Pharmaceuticals (AMLX) stake by 19% in Q3 2026, buying an estimated $85.3M and bringing the position to 19,945,501 shares worth $580M. The position accounts for 0.03% of the portfolio, ranked #475.

Fidelity Investments first reported a position in AMLX in Q1 2022 and has held it in 19 quarters since. 99 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • Fidelity Investments held 19,945,501 shares of Amylyx Pharmaceuticals worth $580M as of Q3 2026.
  • Fidelity Investments bought 3,217,592 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $85.3M.
  • Amylyx Pharmaceuticals made up 0.03% of Fidelity Investments's portfolio in Q3 2026, its #475 holding.
  • Fidelity Investments first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
  • 99 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.